Real-Life Outcomes of Adjuvant Targeted Therapy and Anti-PD1 Agents in Stage III/IV Resected Melanoma

Real-Life Outcomes of Adjuvant Targeted Therapy and Anti-PD1 Agents in Stage III/IV Resected Melanoma

This study was carried out at the Dermatologic Clinic of the University of Turin, Italy, to assess the effectiveness and safety of adjuvant therapy in patients who received either targeted therapy (TT: dabrafenib + trametinib) or immunotherapy (IT: nivolumab or pembrolizumab) for up to 12 months. A...

Full description

Saved in:
Bibliographic Details
Published in:Cancers Vol. 16; no. 17; p. 3095
Main Authors: Roccuzzo, Gabriele, Fava, Paolo, Astrua, Chiara, Brizio, Matteo Giovanni, Cavaliere, Giovanni, Bongiovanni, Eleonora, Santaniello, Umberto, Carpentieri, Giulia, Cangiolosi, Luca, Brondino, Camilla, Pala, Valentina, Ribero, Simone, Quaglino, Pietro
Format: Journal Article
Language:English
Published: Switzerland MDPI AG 06-09-2024
Subjects:
Adjuvant therapy
Adjuvants
Clinical trials
Immunotherapy
Lymph nodes
Lymphatic system
Medical prognosis
Melanoma
Metastases
Metastasis
Mitosis
Patients
PD-1 protein
Pembrolizumab
Skin cancer
Survival
pembrolizumab
melanoma
BRAF
nivolumab
adjuvant
dabrafenib
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:This study was carried out at the Dermatologic Clinic of the University of Turin, Italy, to assess the effectiveness and safety of adjuvant therapy in patients who received either targeted therapy (TT: dabrafenib + trametinib) or immunotherapy (IT: nivolumab or pembrolizumab) for up to 12 months. A total of 163 patients participated, including 147 with stage III and 19 with stage IV with no evidence of disease. The primary outcomes were relapse-free survival (RFS), distant metastasis-free survival (DMFS), and overall survival (OS). At 48 months, both TT and IT approaches yielded comparable outcomes in terms of RFS (55.6-55.4%, = 0.532), DMFS (58.2-59.8%, = 0.761), and OS (62.4-69.5%, = 0.889). Whilst temporary therapy suspension was more common among TT-treated patients compared to IT-treated individuals, therapy discontinuation due to adverse events occurred at comparable rates in both groups. Predictors of relapse included mitoses, lymphovascular invasion, ulceration, and positive sentinel lymph nodes. Overall, the proportion of BRAF-mutated patients receiving IT stood at 7.4%, lower than what was observed in clinical trials.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:2072-6694
2072-6694
DOI:10.3390/cancers16173095